WASHINGTON DC (December 10, 2018) – Today Andrew S. O’Connor is joining the Association for Accessible Medicines (AAM) Government Affairs team as Manager, State Government Affairs.
He will manage the tracking of state legislation and regulations and provide the team with administrative and operational support. Andrew previously served as Legislative Associate, Healthcare and Insurance, at Stateside Associates in Arlington VA. This role called upon him to research projects for clients and to report policy outcomes of key legislation across twenty states. Before coming to Statewide Associates he was a legislative aide to Connecticut House Republicans and a consultant to the House Republican Campaign Committee. In the latter capacity, he advised candidates across Connecticut on their campaigns to be a State Representative in the Connecticut General Assembly.
Andrew has a Bachelor of Arts from the University of Connecticut, where he studied Political Science, with a minor in Communications. He also earned a paralegal certificate from the University of Connecticut.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.